Vericel (VCEL) Reaches $7.55 After 7.00% Up Move; Quinn Opportunity Partners Trimmed Activision Blizzard (ATVI) Holding By $5.48 Million

February 15, 2018 - By Louis Casey

Quinn Opportunity Partners Llc decreased Activision Blizzard Inc (ATVI) stake by 72.81% reported in 2017Q3 SEC filing. Quinn Opportunity Partners Llc sold 85,699 shares as Activision Blizzard Inc (ATVI)’s stock rose 23.27%. The Quinn Opportunity Partners Llc holds 32,000 shares with $2.06M value, down from 117,699 last quarter. Activision Blizzard Inc now has $54.09 billion valuation. The stock increased 2.71% or $1.89 during the last trading session, reaching $71.54. About 3.68 million shares traded. Activision Blizzard, Inc. (NASDAQ:ATVI) has risen 47.83% since February 15, 2017 and is uptrending. It has outperformed by 31.13% the S&P500.

The stock of Vericel Corporation (NASDAQ:VCEL) is a huge mover today! The stock increased 3.42% or $0.25 during the last trading session, reaching $7.55. About 357,643 shares traded. Vericel Corporation (NASDAQ:VCEL) has declined 10.47% since February 15, 2017 and is downtrending. It has underperformed by 27.17% the S&P500.The move comes after 7 months positive chart setup for the $263.55 million company. It was reported on Feb, 15 by Barchart.com. We have $8.08 PT which if reached, will make NASDAQ:VCEL worth $18.45 million more.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $263.55 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

Among 4 analysts covering Vericel (NASDAQ:VCEL), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Vericel had 10 analyst reports since March 11, 2016 according to SRatingsIntel. On Wednesday, August 9 the stock rating was maintained by Piper Jaffray with “Buy”. The company was initiated on Thursday, December 22 by Piper Jaffray. The rating was downgraded by Bank of America on Tuesday, April 5 to “Neutral”. Piper Jaffray maintained Vericel Corporation (NASDAQ:VCEL) on Tuesday, January 2 with “Buy” rating. Piper Jaffray maintained Vericel Corporation (NASDAQ:VCEL) rating on Tuesday, October 3. Piper Jaffray has “Buy” rating and $7.0 target. Needham upgraded the shares of VCEL in report on Friday, March 11 to “Buy” rating. Needham maintained Vericel Corporation (NASDAQ:VCEL) on Wednesday, November 9 with “Buy” rating. The rating was maintained by BTIG Research on Wednesday, August 9 with “Buy”. BTIG Research maintained Vericel Corporation (NASDAQ:VCEL) rating on Tuesday, November 7. BTIG Research has “Buy” rating and $6.0 target.

Analysts await Vericel Corporation (NASDAQ:VCEL) to report earnings on March, 9. They expect $-0.10 EPS, up 28.57% or $0.04 from last year’s $-0.14 per share. After $-0.16 actual EPS reported by Vericel Corporation for the previous quarter, Wall Street now forecasts -37.50% EPS growth.

Among 30 analysts covering Activision Blizzard (NASDAQ:ATVI), 24 have Buy rating, 0 Sell and 6 Hold. Therefore 80% are positive. Activision Blizzard had 130 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Friday, February 9 by KeyBanc Capital Markets. The stock has “Buy” rating by Oppenheimer on Friday, August 4. The stock has “Outperform” rating by Wedbush on Friday, August 5. The stock of Activision Blizzard, Inc. (NASDAQ:ATVI) earned “Buy” rating by Mizuho on Wednesday, August 5. Cowen & Co maintained Activision Blizzard, Inc. (NASDAQ:ATVI) on Monday, July 10 with “Buy” rating. The firm earned “Overweight” rating on Tuesday, September 15 by Barclays Capital. As per Friday, February 9, the company rating was maintained by Credit Suisse. On Friday, November 3 the stock rating was maintained by Robert W. Baird with “Outperform”. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, May 9 report. The firm earned “Buy” rating on Wednesday, June 7 by Morgan Stanley.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: